Hot Canadian Stocks For 2015

Hot Canadian Stocks For 2015: Valeant Pharmaceuticals International Inc(VRX)

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders; Xenazine to treat chorea associated with Huntington?s disease; CeraVe to rebuild and repair skin barrier; and Kinerase, a cosmetic product. The company also provides Zovirax ointment to treat initial genital herpes; Xerese to treat recurrent herpes labialis; Elidel to treat atopic dermatitis; and Acanya and Atralin gels to treat acne vulgaris. In addition, it offers Cesamet to treat nausea and vomiting associated with cancer chemotherapy; Tiazac XC to treat hypertension and angina; Wellbutrin to treat depressive illness; Sublinox to treat insomnia; and Lodalis to treat hypercholesterolemia. Further, the company provides Cold-FX to strengthen immune system; Duromine/Metermine for weight loss; Difflam to treat sore throa ts; and Duro-Tuss and Rikodeine to treat dry and chesty cough, as well as various branded generics for treatments, including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications, and diabetic therapies. Additionally, it offers Bisocard to treat hypertension and angina pectoris; Flucinar, a corticosteroid ointment; and Sachol mouth ulcer gel; Bedoyecta to treat neurotic pain; M.V.I., a hospital dietary supplement for trauma and burns; Tandene to treat fever and headache; Melleril to treat anxiety and depression; and products for therapeutic classes, such as vitamin deficiency, antibacterials, and dermatology. It markets its products in the United States, Canada, Australia, New Zealand, Europe, Latin America, southeast Asia, and South Africa. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 19! 60 and is headquartered in M ississauga, Canada.

Advisors' Opinion:

• [By Dimitra DeFotis]

  Here are insights on the conference call that ensued, fromISI’s biotech and pharmaceutical industry analystMark Schoenbaum,paraphrased:

  Merck wants “bolt-ons” acquisitions (like Idenix Pharmaceuticals (IDIX)) versus big purchases. Moreover, it is not interested in a deal primarily or solely for tax inversion purposes … [That's not ruling out the possibility of buying a foreign company to avoid U.S. taxes, but the language seems contrary to the foreign-merger possibilities for other healthcare companies, includingValeant Pharmaceuticals (VRX), Actavis (ACT), Pfizer (PFE), AbbVie (ABBV), Medtronic (MDT) and evenWalgreen (WAG).] Merck sees a “high likelihood” of success for the four-week Hepatitis C regimen from C-SWIFT when presented at a medical conference this fall. (The combo treatment includes Gilead’s Sovaldi, already on the market, and a Merck regimen.) The company sees “lots of opportunities” to possibly accelerate Food & Drug Administration filings for an experimental immuno-oncology drug for lung cancer patients. It’s excited about the expected Aug. 14 FDA decision on insomnia drug Suvorexant. (Wall Street is bearish on commercial prospects.) Merck expects U.S. volume growth for diabetes drug Januvia (which is roughly 25% of earnings) in the second half of 2014.

  For healthcare investing ideas and insight on so-called tax inversions, see the Barrons.com Q&A with Andy Acker, manager of the Janus Global Life Sciences Fund (JAGLX): “Undervalued Biotech Stocks Help Fund Beat the Index,” July 29. (Subscription required) One insight from Acker:

• [By David Williamson]

  Valeant Pharmaceuticals (NYSE: VRX  ) grows through acquisition, mostly through smaller accretive deals. But management had its elephant guns loaded and after missing out on generic drugmaker ! Actavis b! agged its big game via an $8.7 billion buyout of eye-care heavyweight Bausch & Lomb.

• [By MONEYMORNING]

  Most of that value has come from a few large transactions, notably Valeant Pharmaceutical Intl Inc.'s (NYSE: VRX) $8.7 billion acquisition of Bausch + Lomb, and Actavis PLC's (NYSE: ACT) $8.5 billion purchase of Warner Chillcott PLC.

• [By Sean Williams]

  What: Shares of specialty pharmaceutical company Valeant Pharmaceuticals (NYSE: VRX  ) spiked higher by as much as 17% following a report from The Wall Street Journal that indicates that Valeant may be close to purchasing privately held eye care products maker Bausch & Lomb.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/hot-canadian-stocks-for-2015.html